LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Akcijų sąrašas・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

9.17 8.39

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.44

Max

9.27

Pagrindiniai rodikliai
By Trading Economics
Pajamos	61M 6.8M
Pardavimai	7.4M 156M
P/E Sektoriaus vid.	8.634 50.102
Pelnas, tenkantis vienai akcijai	0.21
Pelno marža	4.356
Darbuotojai	900
EBITDA	28M 35M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+42.01% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	21M 436M
Ankstesnė atidarymo kaina	0.78
Ankstesnė uždarymo kaina	9.17

Naujienos nuotaikos

By Acuity

50%

154 / 344 reitingas Healthcare

Emergent BioSolutions Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-26 16:52; UTC

Svarbiausios naujienos

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

2026-05-26 23:57; UTC

Uždarbis

Sociedad Quimica 1Q Rev $1.76B >SQM

2026-05-26 23:57; UTC

Uždarbis

Sociedad Quimica 1Q EPS $1.28 >SQM

2026-05-26 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026-05-26 21:54; UTC

Uždarbis

Webco Industries 3Q EPS $11.61 >WEBC

2026-05-26 21:54; UTC

Uždarbis

Webco Industries 3Q Sales $179.6M >WEBC

2026-05-26 21:48; UTC

Rinkos pokalbiai

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

2026-05-26 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2026-05-26 20:58; UTC

Įsigijimai, susijungimai, perėmimai

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

2026-05-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-26 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-26 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-26 19:22; UTC

Rinkos pokalbiai

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

2026-05-26 19:17; UTC

Rinkos pokalbiai

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

2026-05-26 18:56; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

2026-05-26 18:03; UTC

Rinkos pokalbiai

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

2026-05-26 17:42; UTC

Rinkos pokalbiai

Grains Await Fresh Trading Catalyst -- Market Talk

2026-05-26 17:33; UTC

Rinkos pokalbiai

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

2026-05-26 17:21; UTC

Rinkos pokalbiai

Canada Faces a Labor Market Squeeze -- Market Talk

2026-05-26 16:52; UTC

Rinkos pokalbiai

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

2026-05-26 16:43; UTC

Rinkos pokalbiai

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

2026-05-26 16:24; UTC

Rinkos pokalbiai

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

2026-05-26 16:21; UTC

Rinkos pokalbiai

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Auto & Transport Roundup: Market Talk

2026-05-26 16:16; UTC

Rinkos pokalbiai

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

2026-05-26 16:01; UTC

Rinkos pokalbiai

Bitcoin Lower as Stress Builds for Holders -- Market Talk

2026-05-26 15:21; UTC

Rinkos pokalbiai

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Akcijų palyginimas

Kainos pokytis

Emergent BioSolutions Inc Prognozė

Kainos tikslas

By TipRanks

42.01% į viršų

12 mėnesių prognozė

Vidutinis 12 USD 42.01%

Aukščiausias 12 USD

Žemiausias 12 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Emergent BioSolutions Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Emergent BioSolutions Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

154 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.